Schrodinger

SDGR

Market cap $1.36B

Overview Fund Activity

18.46 USD

-0.11

0.59%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

18.40

-0.06

0.33%

1 day

-0.59%

5 days

-4.99%

1 month

-4.75%

3 months

-12.92%

6 months

-22.21%

Year to date

-9.51%

1 year

-7.05%

5 years

-65.18%

10 years

-35.54%

About: Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Employees: 787

Healthcare Health Information Services

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

507% more call options, than puts

Call options by funds: $34.7M | Put options by funds: $5.72M

63% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 27

9% more capital invested

Capital invested by funds: $1.31B [Q1] → $1.43B (+$121M) [Q2]

7% more funds holding

Funds holding: 215 [Q1] → 230 (+15) [Q2]

6.87% more ownership

Funds ownership: 103.53% [Q1] → 110.4% (+6.87%) [Q2]

4% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 76

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$19

3% upside

Avg. target

$24

27% upside

High target

$30

63% upside

4 analyst ratings

2 positive

50%

2 neutral

50%

0 negative

0%

Morgan Stanley Vikram Malhorta	$19	Equal-Weight Maintained	18 Aug 2025
Citigroup David Lebowitz	$20	Neutral Downgraded	15 Aug 2025
Barclays Peter Lawson	$25	Overweight Initiated	14 Aug 2025
Keybanc Aleksey Yefremov	$30	Overweight Maintained	14 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about SDGR published over the past 30 days

Zacks Investment Research

Does Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 40.4% in Schrodinger (SDGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect?

Schrödinger, Inc. (SDGR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Schrödinger, Inc. (NASDAQ:SDGR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 11:30 AM EDT Company Participants Ramy Farid - CEO, President & Director Karen Akinsanya - President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships Richie Jain - Executive VP, CFO & Treasurer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to Morgan Stanley's Global Healthcare Conference. I'm Sean Laaman, Head of U.S. Mid-Cap Biotech Equity Research here at the firm.

Schrödinger, Inc. (SDGR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference. The live presentation will take place on Monday, September 8, 2025 at 11:30 a.m. E.T. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery wi.

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 15, 2025, the company granted restricted stock units (RSUs) with respect to 1,875 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement t.

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger Announces Discontinuation of SGR-2921 Program

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a Phase 1 dose-escalation study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Despite early evidence of monotherapy activity observed in the Phase 1 study, based on the profile observed to date, including two emergent events where SGR-2921 was consid.

Schrödinger Announces Discontinuation of SGR-2921 Program

Schrödinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript

Schrödinger, Inc. (NASDAQ:SDGR ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Jaren Irene Madden - Chief Corporate Affairs Officer & Head of Investor Relations Karen Akinsanya - President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships Ramy Farid - CEO, President & Director Richie Jain - Executive VP, CFO & Treasurer Conference Call Participants Brendan Mychal Smith - TD Cowen, Research Division Evan David Seigerman - BMO Capital Markets Equity Research Lili Nsongo - Leerink Partners LLC, Research Division Michael Leonidovich Ryskin - BofA Securities, Research Division Scott Anthony Schoenhaus - KeyBanc Capital Markets Inc., Research Division Sean M. Laaman - Morgan Stanley, Research Division Operator Thank you for standing by.

Schrödinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.74 per share a year ago.

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates

The Motley Fool

Schrödinger (SDGR) Q2 2025 Earnings Transcript

Image source: The Motley Fool.

Schrödinger (SDGR) Q2 2025 Earnings Transcript

Schrödinger Reports Second Quarter 2025 Financial Results

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the quarter ended June 30, 2025.

Schrödinger Reports Second Quarter 2025 Financial Results

Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) will report its second quarter 2025 financial results on Wednesday, August 6, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which.

Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

See News Rankings

Charts implemented using Lightweight Charts™